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ABSTRACT
Mucormycosis is an increasingly frequent, difficult to diagnose, difficult to treat, often fatal infection, especially in patients 
with hyperglycemia from uncontrolled diabetes. Type I (von Gierke) glycogen storage disease is due to inherited deficiency 
of enzymes in glycogen metabolism, which causes hypoglycemia. This report is the case of a patient with von Gierke 
disease and a missed diagnosis of pulmonary mucormycosis. This report illustrates the importance of having a high index 
of suspicion for mucormycosis in the appropriate clinical context. 
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CASE REPORT
This 20-year-old woman from the Northeast 
USA had type I (von Gierke) glycogen storage disease 
and was transferred to a referral hospital for liver 
transplant evaluation. The patient had received a 
living-related renal transplant at age 15 for renal failure 
attributed to her glycogen storage disease. She had 
had a laparoscopic cholecystectomy at age 18. She had 
developed chronic rejection of her renal transplant 
and hemodialysis had to be resumed approximately 
10 months prior, at which point immunosuppression 
was presumably stopped. One week prior to transfer, 
she received a second living-related renal transplant. 
Three days postoperatively, the transplant renal vein 
thrombosed. Five days postoperatively, the new allograft 
was removed. Following the allograft nephrectomy, the 
patient had increasing transaminases, prothrombin 
time, partial thromboplastin time and lactate. 
Her platelet count and hemoglobin fell. She became 
obtunded and hypotensive. The patient was intubated 
and mechanically ventilated. An infusion of dopamine 
was started for blood pressure support. She was given 
platelets, packed red blood cells, fresh frozen plasma, 
cryoprecipitate and desmopressin. She was transferred 
to a referral hospital on postoperative day 7 for liver 
transplant evaluation.
On admission to the referral hospital, the patient’s 
temperature was 36 degrees C, pulse 100/minute, 
respirations 16/minute (on ventilator) and blood 
pressure 110/60 mm Hg. Her abdomen was diffusely 
tender with serous drainage from her surgical drain. 
She was incontinent of stool and had pedal edema. 
Neurologic examination showed a grade III hepatic 
coma, with grimacing to pain. She was mildly 
hyperreflexic. Blood testing showed multi-organ 
biochemical derangement with ammonia 108 uMol/L 
(reference range [RR]: 5-50 uMol/L), lactate 21.7 mEq/L 
(RR: 0.7-1.8 mEq/L), and bil irubin 12.7 mg/dL 
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(RR: 0.3-1.5 mg/dL). Tissue injury was manifested 
by elevated serum aspartate aminotransferase (AST) 
18,895 U/L (RR: <40 U/L), alanine aminotransferase 
(ALT) 2659 U/L (RR: <40 U/L), and amylase 1570 U/L 
(RR: 25-125 U/L). Additional metabolic testing revealed 
serum sodium 136 mEq/L (RR: 136-145 mEq/L), 
potassium 6.2 mEq/L (RR: 3.5-5.1 mEq/L), chloride 
89 mEq/L (RR: 95-110 mEq/L), bicarbonate 11 mEq/L 
(RR: 21-31 mEq/L), calcium 7.3 mg/dL (RR: 8.5-10.5 mg/dL), 
phosphorus 14.3 mg/dL (RR: 2.5-4.5 mg/dL), magnesium 
1 . 7  m E q / L  ( R R :  1 . 6 - 2 . 5  m E q / L ) ,  g l u c o s e 
331 mg/dL (RR: 70-110 mg/dL), blood urea nitrogen 
8 mg/dL (RR: 9-20 mg/dL), and creatinine 3.7 mg/dL 
(RR: 0.8-1.5 mg/dL). The patient’s hemoglobin was 
7.4 g/dL (RR: 11.7-15.7 g/dL), and white blood 
cell count 10,100/mm3 (RR: 4,000-10,000/mm3). 
She was coagulopathic with platelets 52,000/mm3 
(RR: 140,000-440,000/mm3), prothrombin time 
(PT) 21.8 seconds (RR: 10.5-13 seconds), and 
partial thromboplastin time (PTT) 57.8 seconds 
(RR: 25-33 seconds). Arterial blood showed pH 7.12, 
PCO2 32 mm Hg and PO2 134 mm Hg. Chest x-ray 
showed no pulmonary edema.
The patient was admitted with diagnoses of 
fulminant hepatic failure, coagulopathy, metabolic 
acidosis, renal fai lure and anemia. Computed 
tomography (CT) scan of the head showed no 
intracranial bleeding. Transcranial Doppler examination 
showed slightly increased cerebral blood flow. 
CT scan of the abdomen showed an enlarged liver, 
and an ultrasound examination of the abdomen had 
findings that suggested the possibility of hepatic vein 
thrombosis, but was not definitive. The patient was 
given red blood cells, platelets, fresh frozen plasma, 
cryoprecipitate, bicarbonate, and started on slow 
continuous ultrafiltration dialysis. Cefotetan and 
vancomycin therapy were started.
The following day, the patient was weaned 
from dopamine. Her transaminase values decreased 
and her lactate decreased to 19.1 mEq/L. Abdominal 
CT scan showed a lower chest infiltrate consistent 
with infection or posttransplant lymphoproliferative 
disorder. Her amylase rose to 3113 U/L. Blood cultures 
drawn on admission were reported positive for gram 
positive cocci in pairs and chains. Later that day, the 
patient developed an unstable heart rhythm. She was 
started on esmolol.
On the third day at the referral hospital, the 
patient remained unresponsive. Her lactate and 
transaminases continued to fall, but lipase increased 
above 4000 U/L and bilirubin climbed to 22 mg/dL. 
The admission blood culture isolate was identified as 
Enterococcus faecalis. Arterial line catheter tip culture 
from admission yielded Enterococcus faecium and 
Enterococcus faecalis.
On the fourth day, the patient continued in hepatic 
coma and shock, with metabolic acidosis (lactate 
27.9 mEq/L). She had diffuse 2+ edema and bilateral 
rhonchi. Blood and sputum cultures from the third day 
were positive for Enterococcus faecalis. At 13:30, the 
patient’s Swan Ganz right heart catheter was changed 
and culture of the catheter tip subsequently yielded 
100 colonies of Enterococcus faecalis. At 18:28, the 
patient’s bilirubin was 25.8 mg/dL, ALT 619 U/L, 
AST 5224 U/L, PT 20.4 seconds, PTT 34.8 seconds, 
sodium 129 mEq/L, potassium 3.3 mEq/L, chloride 
81 mEq/L, bicarbonate 19 mEq/L, blood urea nitrogen 
3 mg/dL, creatinine 1.7 mg/dL, glucose 504 mg/dL, 
white blood cell count 8,100/mm3 (83% segmented 
neutrophils, 8% bands, 2% lymphocytes, 7% 
monocytes), hemoglobin 10.5 g/dL, and platelets 
24,000/mm3.
Considering that the patient’s liver might be the 
anatomic source of her life-threatening enterococcal 
sepsis and was non-functional, a decision was 
reached to perform an emergency hepatectomy 
with a portocaval shunt and hope of soon finding a 
suitable liver for transplantation. During the procedure, 
the patient needed 91 units of blood, 30 units of 
platelets, and 24 units of cryoprecipitate and fresh 
frozen plasma. As the surgeons were closing the 
abdomen, the patient became bradycardic and started 
bleeding through her endotracheal tube. Arterial 
blood showed pH 7.15, PCO2 27 mm Hg and PO2 
59 mm Hg. Cardiopulmonary resuscitation including 
pericardiocentesis with removal of 200 ml of fluid was 
to no avail.
The explanted l iver weighed 3700 grams 
(RR: <1800 grams) and showed near-total necrosis with 
massive hemorrhage, but no significant inflammation 
and no organisms on special stains. Neither the surgical 
pathology examination of the explanted liver nor the 
autopsy showed hepatic vein thrombosis.
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AUTOPSY FINDINGS
Postmortem examination revealed massive internal 
hemorrhage in the lungs, pleural spaces, gastrointestinal 
tract, genitourinary tract and left adrenal gland. 
Autopsy also demonstrated mucormycosis in left upper 
lobe lung with vascular invasion and areas of associated 
hemorrhagic pulmonary infarction (Figure 1).
In areas without infarction or hemorrhage, the 
lungs had moderate alveolar edema (Figure 2).
Postmortem lung cultures yielded Rhizopus. 
The remaining al lograft kidney (the f irst one 
transplanted) showed moderate chronic rejection. 
The native kidneys showed diffuse sclerosis of 
glomeruli with interstitial edema, fibrosis and 
tubular atrophy. The autopsy also showed a 4.8 cm 
superior vena cava peri-catheter thrombus, fibrin 
thrombi in glomeruli and blood vessels consistent 
with disseminated intravascular coagulation, and 
multifocal pancreatitis.
DISCUSSION
The antemortem and postmortem evidence 
suggests that the immediate primary cause of this 
patient’s death was massive internal bleeding, 
associated with pulmonary mucormycosis, gut 
ischemia, coagulopathy and the anhepatic state. 
The enterococcal sepsis preceding this was presumably 
from the intestines, possibly due to ischemia, but 
the brief immunosuppression for the failed second 
renal transplantation may have contributed. Bleeding 
from left upper lobe lung, with blood pouring into 
the endotracheal tube, seems to have precipitating 
the patient’s terminal cardiopulmonary arrest. This 
pulmonary bleeding was related to angioinvasive 
pulmonary mucormycosis.
Lung is often the first site of mucormycosis, as 
exemplified in this case. The nose is even more often 
the first site of mucormycosis.1 The respiratory tract, 
upper or lower, is usually the first site of infection 
because infection usually starts with inhalation of 
spores. These spores are ubiquitous in the air all around 
the world.2 Infection is not with the inhaled resting 
spore forms, but with hyphal forms of the mucoralean 
fungi. One virulence factor of the mucoralean fungi 
is rapid germination from spores to hyphae.3 Rapid 
growth of the hyphae is another virulence factor. 
Rhizopus species inhibit phagosome maturation in 
macrophages by the melanin on the spore surface.2 
Rhizopus species also resist being damaged or killed by 
decreasing the oxidative burst of phagocytes, which is 
another virulence factor.3 Spore coat protein CotH of 
mucoralean fungi binds to glucose-regulated protein 78 
(GRP78) on endothelial cells, promoting angioinvasion, 
which results in thrombosis and tissue necrosis, yet 
another virulence factor.2 The endothelial expression 
of GRP78 is increased in diabetic ketoacidosis, which 
brings us to the host factors in mucormycosis.
Figure 1. Photomicrograph of the lung showing an area 
of hemorrhagic infarction shows large pauciseptate 
fungal hyphae, with low protein content giving some 
hyphae an empty appearance and one of these with 
right-angle branching (H&E, 250X).
Figure 2. Photomicrograph of the lung showing area 
of alveolar edema shows fungal hyphae with random-
angle branching and collapse in the crumpled ribbon 
configuration characteristic of mucormycosis (H&E, 250X).
How could hypoglycemia-inducing glycogen storage disease lead to hyperglycemia-induced mucormycosis?
4-6 Autops Case Rep (São Paulo). 2020 Jan.-Mar.;10(1):e2020149
Mucormycosis is rare in patients without 
uncontrolled diabetes, neutropenia, immunosuppression 
or hematologic malignancy.1 These conditions are 
all becoming more common and the incidence of 
mucormycosis is similarly increasing.4 Pulmonary 
mucormycosis makes up a quarter of the cases and has 
a fatality of approximately 50%. The most prevalent 
underlying disease in patients with pulmonary 
mucormycosis, in 51 to 79% of cases, is hematologic 
malignancy.1 Among patients with hematologic 
malignancy and pulmonary mucormycosis, specific risk 
factors for this infection are neutropenia (80% of cases), 
corticosteroid therapy (26%), stem cell transplantation 
(24%), diabetes (18%), and graft-versus-host disease 
(10%).1 The patient of this case report underwent 
brief immunosuppression for 5 days for her second 
renal transplantation, ending 5 days before her 
demise, but her last lymphocyte count was 162/mm3 
(RR: 1,000-4,200/mm3), suggesting that she had 
residual immunosuppression predisposing her to 
infection.
Pulmonary mucormycosis can be difficult to 
recognize because symptoms of the infection are 
nonspecific. Clinical manifestations, which correlate 
with angioinvasion, include fever, cough, chest 
pain, dyspnea and hemoptysis.1 On radiologic 
imaging, pulmonary mucormycosis presents most 
often as nodules, areas of consolidation, cavitary 
lesions or pleural effusion.5 On CT scan, nodules of 
mucormycosis may have surrounding ground-glass 
opacity (halo sign) or a central ground-glass opacity 
may have surrounding consolidation (reverse halo 
sign). Reverse halo sign is particularly suggestive of 
mucormycosis.5,6 In the patient of this case report, 
the lungs had hemorrhages and edema in addition to 
mucormycosis, which likely obscured findings typical 
of mucormycosis.
The diagnosis of mucormycosis is challenging.7 
The  agen t s  o f  muco rmycos i s  do  no t  have 
1,3-beta-D-glucan or galactomannan in their 
cell walls, so serum tests for beta-D-glucan and 
galactomannan are not helpful in making the diagnosis 
of mucormycosis. It relies on the identification of 
organisms in tissue by histopathology with culture 
confirmation, but culture often yields no growth, 
leaving the pathologist’s identification of this type of 
mycosis as the only basis for the diagnosis. Fortunately, 
Rhizopus and the other agents of mucormycosis do 
have morphology distinct from other fungal pathogens: 
large hyphae with scant random-angle branching, 
empty-appearing due to low protein content, and 
collapse in a crumpled ribbon configuration.8,9 This 
morphology is illustrated in the case of this report. 
The pathologist’s diagnosis in this case was confirmed 
by culture, but the agents of mucormycosis can 
colonize the airways or be contaminants in cultures, 
so the isolation of these fungi in a culture does not 
prove infection. Culture results must be interpreted 
in the context of the patient’s symptoms, signs, and 
underlying disease to determine whether antifungal 
therapy should be started.
Mucormycosis typically has a rapid clinical 
progression.7 A clinician must think of this infection 
in the appropriate clinical setting and quickly pursue 
invasive testing in order to establish a diagnosis 
as early as possible. Diabetic ketoacidosis and 
neutropenia are two of the most common clinical 
settings for mucormycosis. Diplopia in a patient with 
diabetic ketoacidosis or hemoptysis in a patient with 
neutropenia should immediately suggest the diagnosis 
of mucormycosis. Black tissue necrosis in the nose, 
periorbital region or other sites of infection is the 
gross pathologic hallmark of mucormycosis.7,9 To be 
successful, therapy must be prompt.
The treatment of mucormycosis is challenging.7 
Rhizopus and the other agents of mucormycosis are 
not susceptible to most antifungal drugs, including 
voriconazole. Successful treatment often requires 
a combination of intravenous amphotericin B (lipid 
formulation) and surgical debridement of necrotic 
infected tissue. Wide debridement to include 
surrounding healthy-appearing tissue is necessary 
because the hyphae invade so rapidly that the leading 
edge of infected tissue is not visibly necrotic. Global 
guidelines for the diagnosis and management of 
mucormycosis have recently been promulgated.9 
Successful treatment frequently depends on reversing 
the underlying condition such as neutropenia or 
diabetic ketoacidosis that allowed infection by 
mucoralean fungi.
This patient’s underlying condition was glycogen 
storage disease type I, also known as von Gierke 
disease, which is an inherited disorder caused by 
deficiencies of enzymes in glycogen metabolism.10 
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It was first described by von Gierke in 1929 who 
reported excessive hepatic and renal glycogen in the 
autopsies of two children. In the most common form 
of type I glycogen storage disease, there is a deficiency 
of glucose-6-phosphatase, which cleaves glycogen to 
glucose, leading to hypoglycemia and lactic acidosis, 
Patients present with manifestations of hypoglycemia 
and metabolic acidosis, typically around 3 to 4 months 
of age. Diet and lifestyle changes are made to prevent 
the primary concern of the disease, hypoglycemia. 
Initially, infants are fed soy-based, sugar-free formula 
on demand every 2 to 3 hours. Cornstarch has been 
used for the treatment of hypoglycemia since its 
slow digestion provides a steady release of glucose. 
When an infant’s sleep duration becomes longer than 
3 to 4 hours, it is important to prevent hypoglycemia 
during sleep, which can be done by administering tube 
feed via a nasogastric tube or a surgically placed gastric 
tube.10 Prevention of hypoglycemia is paramount in the 
treatment of von Gierke disease.
How could this patient’s hypoglycemia-inducing 
glycogen storage disease have led to mucormycosis, 
which is typically hyperglycemia-induced? The patient’s 
blood glucose was 331 mg/dL on admission to the 
referral hospital and 504 mg/dL 8 hours before she 
died in the operating room. The physicians at both 
hospitals seem to have been so worried about the 
possibility of hypoglycemia that they gave so much 
glucose that the patient had hyperglycemia equivalent 
to diabetes out of control.
CONCLUSION
This is the report of a case of a missed diagnosis 
of pulmonary mucormycosis in a patient with glycogen 
storage disease. The patient was critically ill, with 
multi-organ system failure and enterococcal sepsis, 
following a failed kidney transplantation. With the 
stress response to her critical illness, the glucose 
infusion to prevent hypoglycemia from the patient’s 
underlying disease resulted in hyperglycemia in the 
range of diabetic ketoacidosis, a major risk factor 
for mucormycosis. One lesson from this case might 
be expressed: Watch out for mucormycosis. Another 
lesson might be expressed: Be careful not to overcorrect 
for hypoglycemia. Primum non nocere.
Informed consent by the next of kin was retained 
by the institution where the autopsy was performed, 
whose institutional review board waives approval of 
case report manuscripts.
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